An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124®)

Official Title: An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124®)

This is a Phase 3, multicenter, open-label, safety and efficacy study of ataluren in patients with nonsense mutation cystic fibrosis who participated in the previous Phase 3 study with ataluren (PTC124-GD-009-CF; Study 009).

ClinicalTrials.gov ID: NCT02107859

Principal Investigator: McColley, Susanna, MD

Study Type: Interventional

Currently Recruiting Patients: No

Contact Information:

Naiomi Nemoto

Clinical Research Coordinator

312.227.6266

Specialties & Conditions

Patients & Visitors

Plan Your Visit

While You're Here

After Your Visit

Research Innovation

An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124®)

Official Title: An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124®)

Contact Information:

Find

Get in Touch

Get to Know Us

For Healthcare Professionals